Skip to main content

We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.

Join Now
Sign In

Member Sign In

Username or Email Address

Password

Keep Me Signed In What does "Remember Me" do?

Don't Know Your Password?
Help

Join Now
Sign In

Member Sign In

Username or Email Address

Password

Keep Me Signed In

Don't Know Your Password?

Zacks

more

Oramed Pharmaceuticals (ORMP)

(Delayed Data from NSDQ)

$2.47 USD

+0.05 (2.07%)

Updated Sep 19, 2024 03:59 PM ET

After-Market: $2.47 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	23.68%
2	Buy	17.55%
3	Hold	9.21%
4	Sell	4.93%
5	Strong Sell	2.36%
S&P	500	10.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

Top 26% (65 out of 251)

Industry: Medical - Products

View All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

View Cart/Checkout

Oramed Pharmaceuticals Inc. [ORMP]

Reports for Purchase

Showing records 1 - 20 ( 81 total )

Company: Oramed Pharmaceuticals Inc.

Industry: Medical - Products

Record: 1

05/20/2024

Pages: 5

Awaiting Pipeline Clarity; 1Q24 Financials; Reiterate Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Oramed Pharmaceuticals Inc.

Industry: Medical - Products

Record: 2

01/02/2024

Pages: 5

Oral Drug Delivery Joint Venture; Debt Transaction; Reiterate Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: Oramed Pharmaceuticals Inc.

Industry: Medical - Products

Record: 3

05/24/2023

Pages: 4

Potential Hope for Oral Insulin; 1Q23 Financials; Reiterate Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: Oramed Pharmaceuticals Inc.

Industry: Medical - Products

Record: 4

03/13/2023

Pages: 4

Financial Results Reported; Reiterate Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: Oramed Pharmaceuticals Inc.

Industry: Medical - Products

Record: 5

02/14/2023

Pages: 4

Strategic Options Being Explored; Reiterate Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: Oramed Pharmaceuticals Inc.

Industry: Medical - Products

Record: 6

01/17/2023

Pages: 5

ORMD-0801 Phase 3 Failure; Downgrading to Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: Oramed Pharmaceuticals Inc.

Industry: Medical - Products

Record: 7

01/03/2023

Pages: 5

ORMD-0801 Pivotal Data Readout Imminent; 3Q22 Financials; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: Oramed Pharmaceuticals Inc.

Industry: Medical - Products

Record: 8

08/15/2022

Pages: 5

ORMD-0801 Pivotal Top-Line Data Approaches; 2Q22 Financials; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: Oramed Pharmaceuticals Inc.

Industry: Medical - Products

Record: 9

08/02/2022

Pages: 5

Second Pivotal Oral Insulin Trial Reaches 50% Enrollment; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: Oramed Pharmaceuticals Inc.

Industry: Medical - Products

Record: 10

07/11/2022

Pages: 5

Pipeline Update Underscores Near-Term Catalysts; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: Oramed Pharmaceuticals Inc.

Industry: Medical - Products

Record: 11

04/13/2022

Pages: 5

Liver Disease-Focused European Patent Granted; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: Oramed Pharmaceuticals Inc.

Industry: Medical - Products

Record: 12

03/31/2022

Pages: 6

KOL Event Underscores ORMD-0801 Value Proposition; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 12.50

Research Provided by a Third Party

Company: Oramed Pharmaceuticals Inc.

Industry: Medical - Products

Record: 13

03/17/2022

Pages: 5

ORMD-0801 Phase 2 NASH Trial Completes Enrollment; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: Oramed Pharmaceuticals Inc.

Industry: Medical - Products

Record: 14

01/18/2022

Pages: 6

2022 Outlook Promises Multiple Catalysts; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 12.50

Research Provided by a Third Party

Company: Oramed Pharmaceuticals Inc.

Industry: Medical - Products

Record: 15

12/30/2021

Pages: 6

Co-operation and Purchase Agreement With Vietnam-Based Firm; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 12.50

Research Provided by a Third Party

Company: Oramed Pharmaceuticals Inc.

Industry: Medical - Products

Record: 16

12/15/2021

Pages: 6

Oravax COVID-19 Vaccine Clinical Development Begins; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 12.50

Research Provided by a Third Party

Company: Oramed Pharmaceuticals Inc.

Industry: Medical - Products

Record: 17

11/29/2021

Pages: 6

ORMD-0801 Phase 3 Trial Progress; F2021 Financials; Raising PT to $32

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 12.50

Research Provided by a Third Party

Company: Oramed Pharmaceuticals Inc.

Industry: Medical - Products

Record: 18

09/28/2021

Pages: 10

ValuEngine Detailed Valuation Report for ORMP

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Oramed Pharmaceuticals Inc.

Industry: Medical - Products

Record: 19

01/29/2021

Pages: 5

Pipeline Advancing on Multiple Fronts; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Oramed Pharmaceuticals Inc.

Industry: Medical - Products

Record: 20

01/22/2021

Pages: 4

ORMD-0801 Phase 3 Program Patient Dosing Initiated; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

previous
1
2
3
4
5
next

// eof